Who are we?


Signup for

Online registration

Log in to register
your trial

Search a trial




van CCT (UK)

van CCT (UK)

Tyrosine supplementatie in ouderen

- candidate number21044
- NTR NumberNTR4938
- ISRCTNISRCTN no longer applicable
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR25-nov-2014
- Secondary IDsNL49758.091.14 ABR 49758
- Public TitleTyrosine supplementatie in ouderen
- Scientific TitleNeuro-cognitive effects of tyrosine supplementation in older adults
- hypothesisWe verwachten dat tyrosine response inhibitie en werkgeheugen zal beïnvloeden via de prefrontal cortex of het striatum. We hypothesize that tyrosine will affect response inhibition and working memory by acting on either the prefrontal cortex or the striatum.
- Healt Condition(s) or Problem(s) studiedOlder adults, Healthy living
- Inclusion criteriaIn order to be eligible to participate in this study, subjects must meet all of these criteria: - Age: 60-75 years old (similar to other studies, for review (Turner & Spreng, 2012)) - Dutch as a mothertongue - Right-handed - Willing to perform tasks in the MRI scanner, to come to the centre on three occasions, consuming tyrosine or a placebo and willing to fast the night before the two test sessions.
- Exclusion criteriaA potential subject who meets any of the following criteria will be excluded from participation in this study : - Clinical dementia as measured by Mini Mental State Examination score < 24) - Severe depression or anxiety as measured by HADS score > 11 - Estimated IQ < 85 (based on Nederlandse Leestest voor Volwassenen (NLV) -score) - (History of) clinically significant psychiatric disorder - (History of) clinically significant neurological disorder, such as brain infarct, Parkinson’s Disease, chronic migraine, Diabetes Mellitus - First degree family history of schizophrenia, bipolar disorder or major depressive disorder - Thyroid problems and low-protein diet - Endocrine or metabolic disorders such as hepatic or renal problemsUnder treatment for cardiac or vascular diseases and use medication for these conditions; - abnormal blood pressure < 90/60mmHg or > 160/90 mmHg (to be determined during the intake session) - Using medication that can interfere with tyrosine’s action; monoamine oxidase inhibitors and other antidepressants, sympathomimetic amines, and opioids - General medical conditions, such as repetitive strain injury (RSI) or sensori-motor handicaps, blindness or colorblindness, as judged by the investigator - (History of) abuse of drugs or alcohol - Habitual smoking, i.e. more than a pack of cigarettes per week - Participation, current or within the past twelve months, in a specific cognitive training study or previous study using the same paradigm as the current study - Contra-indications for MRI: o Metal objects or fragments in the body that cannot be taken out o Active implants in the body o Using medical plasters o Epilepsy o Previous head surgery o Claustrophobia
- mec approval receivedyes
- multicenter trialno
- randomisedyes
- masking/blindingDouble
- controlPlacebo
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 26-nov-2014
- planned closingdate31-dec-2015
- Target number of participants26
- Interventions150 mg/kg bodyweight tyrosine mixed in banana flavoured yoghurt
- Primary outcomePerformance and brain signal on response inhibition task and working memory task, performance on effort discounting task and several neuropsychological tasks.
- Secondary outcomecatecholamine metabolites in urine
- Timepointstwo timepoints, measurements starts 90 minutes after acute administration of tyrosine or placebo
- Trial web site
- statusinclusion stopped: follow-up
- Sponsor/Initiator Donders Institute for Brain, Cognition, and Behaviour, Centre for Cognition, Radboud University Nijmegen
- Funding
(Source(s) of Monetary or Material Support)
- Publications
- Brief summary
- Main changes (audit trail)
- RECORD25-nov-2014 - 27-feb-2016

  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar